jj
agrees
bn
guidant
deal
pharmaceutical
giant
johnson
johnson
agreed
buy
medical
technology
firm
guidant
bn
â£bn
guidant
key
producer
equipment
combats
heart
problems
implant
defibrillators
pacemakers
analysts
said
deal
aimed
offsetting
johnson
johnsons
reliance
slowing
drug
business
also
pointed
mergers
likely
drug
healthcare
industries
fragmented
pressure
cut
costs
number
johnson
johnsons
products
facing
patent
expirations
company
also
battling
fierce
competition
generic
products
meanwhile
demand
defibrillators
give
heart
small
electric
shock
irregular
heartbeat
rhythm
detected
expected
increase
analysts
said
move
johnson
johnson
widely
expected
firm
pay
guidant
share
wednesdays
closing
price
analysts
say
us
antitrust
regulators
could
force
firms
shed
overlapping
stent
operations
stents
tubes
used
keep
artery
open
unblocked
